Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 9/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3328459 | 0.74 | HSD11B1 (1.00) | HSD11B1CYP3A4MEN1KMT2ALMNA | |
| SCHEMBL3323237 | 0.71 | HSD11B1 (0.57) | HSD11B1CYP3A4MEN1KMT2AALDH1A1 | |
| SCHEMBL3323999 | 0.71 | HSD11B1 (0.56) | HSD11B1CYP3A4MEN1KMT2AALDH1A1 | |
| SCHEMBL3327883 | 0.70 | HSD11B1 (0.65) | HSD11B1CYP3A4MEN1KMT2ALMNA | |
| SCHEMBL3323435 | 0.70 | HSD11B1 (0.64) | HSD11B1CYP3A4MEN1KMT2ALMNA | |
| SCHEMBL3455152 | 0.69 | HSD11B1 (0.71) | HSD11B1CYP3A4MEN1KMT2A | |
| SCHEMBL15273712 | 0.69 | HTR2C (0.42) | SMN1; SMN2 | |
| SCHEMBL13981626 | 0.68 | KCNH2 (0.39) | SMN1; SMN2 | |
| SCHEMBL3323691 | 0.68 | HSD11B1 (0.64) | HSD11B1CYP3A4MEN1KMT2ALMNA | |
| SCHEMBL3322230 | 0.68 | HSD11B1 (0.64) | HSD11B1CYP3A4MEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100120789-A1 | Compound | STERIX LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
| US-20100120789-A1 | Compound | STERIX LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
| US-20090042929-A1 | 11-Beta-Hydroxysteroid Dehydrogenase Inhibitors | STERIX LIMITED (GB) | 2009-02-12 | — | — | US | disclosed |
| US-20090042929-A1 | 11-Beta-Hydroxysteroid Dehydrogenase Inhibitors | STERIX LIMITED (GB) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042929-A1 | 11-Beta-Hydroxysteroid Dehydrogenase Inhibitors | HSD3B1, HSD3B2, HSD11B1 | HSD11B1 3/4885CYP3A4 72/4885MEN1 3474/4885 |
| US-20100120789-A1 | Compound | NR0B2, NR0B1, NR4A1 | HSD11B1 73/4885CYP3A4 100/4885MEN1 2608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.